antibody-therapy

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 66/100

   Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France

   ✓ Peer-reviewed alzhub usefulness score 66 out of 100. The journal of prevention of Alzheimer's disease · 2026-10-14 · Treatments

   Lecanemab was the first amyloid-targeting monoclonal antibody approved by the European Commission for treating patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD).

   • Treatments
   • Care Services
   • Biomarkers
2. 83/100

   Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis

   ✓ Peer-reviewed alzhub usefulness score 83 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026-10-02 · Treatments

   ARIA remains a significant safety concern in anti-amyloid mAb therapy, with incidence and severity influenced by genetic, neuroimaging, and treatment-related factors.

   • Treatments
   • Risk Factors
   • Side Effects
3. 50/100

   Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of thrombosis and thrombolysis · 2026-08-20 · Treatments

   Anti-amyloid monoclonal antibodies such as lecanemab are increasingly used to treat Alzheimer's disease (AD) and are associated with amyloid-related imaging abnormalities (ARIA), including hemorrhagic findings (ARIA-H).

   • Treatments
4. 47/100

   The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neurology · 2026-05-08 · Treatments

   Multimodal neuroimaging plays an indispensable role in the diagnosis, monitoring, and therapeutic evaluation of monoclonal antibody (mAb) therapies for Alzheimer's disease (AD).

   • Treatments
   • Brain Scans
   • Side Effects
5. 45/100

   [Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Expert Recommendation for Standard MRI Protocol]

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the Korean Society of Radiology · 2025-01-24 · Treatments

   The introduction of anti-amyloid therapies for Alzheimer's disease (AD), such as lecanemab (Lequembi ® ), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI.

   • Treatments
   • Brain Scans
   • Side Effects

All topic tags with their study counts